Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jul;32(1):39–44. doi: 10.1111/j.1365-2125.1991.tb05610.x

The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

N Ferry 1, N Bernard 1, N Pozet 1, E Gardes 1, M Bruguier 1, G Cuisinaud 1, J Sassard 1
PMCID: PMC1368490  PMID: 1888640

Abstract

1. Ten healthy subjects received two treatments: a single 1 g oral dose of nalidixic acid (NA) followed 1 h later by either an infinitesimal dilution of the drug (NA 7CH) or by succussed water which served as placebo. The study was repeated 18 months later in 10 different subjects. 2. A further 10 healthy subjects received three treatments: a single 100 mg oral dose of atenolol (AT) followed 3 h later by either placebo or a dilution of AT (AT 7CH) or of bisoprolol (BI 7CH). The homoeopathic preparations were administered by the sublingual route. 3. In the first NA experiment NA 7CH significantly shortened the elimination half-life of NA from 8.6 +/- 2.2 (placebo) to 6.4 +/- 1.6 h (NA 7CH). In the second NA experiment none of the pharmacokinetic parameters was modified significantly by the administration of NA 7CH. Neither AT 7CH nor BI 7CH modified the pharmacokinetics of AT.

Full text

PDF
39

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benveniste J. The human basophil degranulation test as an in vitro method for the diagnosis of allergies. Clin Allergy. 1981 Jan;11(1):1–11. doi: 10.1111/j.1365-2222.1981.tb01559.x. [DOI] [PubMed] [Google Scholar]
  2. Cuisinaud G., Ferry N., Pozet N., Zech P. Y., Sassard J. Nalidixic acid kinetics in renal insufficiency. Br J Clin Pharmacol. 1982 Oct;14(4):489–493. doi: 10.1111/j.1365-2125.1982.tb02017.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cuisinaud G., Ferry N., Seccia M., Bernard N., Sassard J. Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography. J Chromatogr. 1980 Mar 14;181(3-4):399–406. doi: 10.1016/s0378-4347(00)81142-1. [DOI] [PubMed] [Google Scholar]
  4. Davenas E., Beauvais F., Amara J., Oberbaum M., Robinzon B., Miadonna A., Tedeschi A., Pomeranz B., Fortner P., Belon P. Human basophil degranulation triggered by very dilute antiserum against IgE. Nature. 1988 Jun 30;333(6176):816–818. doi: 10.1038/333816a0. [DOI] [PubMed] [Google Scholar]
  5. Ferley J. P., Zmirou D., D'Adhemar D., Balducci F. A controlled evaluation of a homoeopathic preparation in the treatment of influenza-like syndromes. Br J Clin Pharmacol. 1989 Mar;27(3):329–335. doi: 10.1111/j.1365-2125.1989.tb05373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ferry N., Cuisinaud G., Pozet N., Zech P. Y., Sassard J. Influence du probénécide sur la pharmacocinétique de l'acide nalidixique. Therapie. 1982 Nov-Dec;37(6):645–649. [PubMed] [Google Scholar]
  7. Ferry N., Cuisinaud G., Pozet N., Zech P. Y., Sassard J. Nalidixic acid kinetics after single and repeated oral doses. Clin Pharmacol Ther. 1981 May;29(5):695–698. doi: 10.1038/clpt.1981.97. [DOI] [PubMed] [Google Scholar]
  8. Ferry N., Cuisinaud G., Sassard J., Pozet N., Zech P. Y. Pharmacokinetics of nalidixic acid associated with sodium citrate. Biopharm Drug Dispos. 1984 Jul-Sep;5(3):211–218. doi: 10.1002/bdd.2510050303. [DOI] [PubMed] [Google Scholar]
  9. LAPP C., WURMSER L., NEY J. Mobilisation de l'arsenic fisé chez le cobaye sous l'influence de doses infinitésimales d'arséniate de sodium. Therapie. 1958;13(1):46–55. [PubMed] [Google Scholar]
  10. LAPP C., WURMSER L., NEY J. Mobilisation de l'arsenic fixe chez le cobaye sous l'influence de doses infinitésimales d'arséniate de sodium. Therapie. 1955;10(4):625–638. [PubMed] [Google Scholar]
  11. MCCHESNEY E. W., FROELICH E. J., LESHER G. Y., CRAIN A. V., ROSI D. ABSORPTION, EXCRETION, AND METABOLISM OF A NEW ANTIBACTERIAL AGENT, NALIDIXIC ACID. Toxicol Appl Pharmacol. 1964 May;6:292–309. doi: 10.1016/0041-008x(64)90070-5. [DOI] [PubMed] [Google Scholar]
  12. McAinsh J. Clinical pharmacokinetics of atenolol. Postgrad Med J. 1977;53 (Suppl 3):74–78. [PubMed] [Google Scholar]
  13. Mcainsh J., Simpson W. T., Holmes B. F., Young J., Ellis S. H. Bioavailability of atenolol formulations. Biopharm Drug Dispos. 1980 Oct-Dec;1(6):323–332. doi: 10.1002/bdd.2510010604. [DOI] [PubMed] [Google Scholar]
  14. Männistö P. T. Pharmacokinetics of nalidixinic acid and oxolinic acid in healthy women. Clin Pharmacol Ther. 1976 Jan;19(1):37–46. doi: 10.1002/cpt197619137. [DOI] [PubMed] [Google Scholar]
  15. Reeves P. R., Barnfield D. J., Longshaw S., McIntosh D. A., Winrow M. J. Disposition and metabolism of atenolol in animals. Xenobiotica. 1978 May;8(5):305–311. doi: 10.3109/00498257809060955. [DOI] [PubMed] [Google Scholar]
  16. Reilly D. T., Taylor M. A., McSharry C., Aitchison T. Is homoeopathy a placebo response? Controlled trial of homoeopathic potency, with pollen in hayfever as model. Lancet. 1986 Oct 18;2(8512):881–886. doi: 10.1016/s0140-6736(86)90410-1. [DOI] [PubMed] [Google Scholar]
  17. Sassard J., Pozet N., McAinsh J., Legheand J., Zech P. Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol. 1977 Nov 14;12(3):175–180. doi: 10.1007/BF00609856. [DOI] [PubMed] [Google Scholar]
  18. Vree T. B., Wijnands W. J., Baars A. M., Hekster Y. A. Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation. Pharm Weekbl Sci. 1988 Oct 14;10(5):193–199. doi: 10.1007/BF01956870. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES